Frontline vaccination with the B-cell peptide compound HER-Vaxx (IMU-131), combined with standard-of-care chemotherapy induces high levels of HER2-specific antibodies mediating ADCC and intracellular phosphorylation inhibition resulting in overall survival benefit in patients with HER2+ metastatic or advanced gastric/GEJ adenocarcinoma – Final results from Phase II/HERIZON study

Presented by Joshua Tobias Ph.D. Medical University of Vienna

Oncolytic virus CF33-hNIS for the treatment of advanced cancer

Presented by Dr. Daneng Li from the City of Hope National Comprehensive Cancer Centre

A Phase I Safety and Tolerability Study of VAXINIA (CF33-hNIS), a Novel Chimeric Oncolytic Poxvirus, Administered Intratumorally or Intravenously in Adults with Metastatic or Advanced Solid Tumors. 

Presented by Dr Daneng Li MD City of Hope and Imugene Executive Director of Clinical Science Dr Sharon Yavrom.

Tobias etal. HERIZON: A Phase 2 study of HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine plus standard of care hemotherapy in patients with HER2+ advanced stomach Cancer — dose-dependent anti-cancer antibodies correlating with improved clinical outcome

Tobias etal. Prevention of metastasis formation by combination therapy targeting Her2 and PD-L1 in Her2-expressing tumors based on observed efficacious vaccination against Her2-positive tumors

Boyer etal. IMPRINTER: An Open Label, Multi-Center, Dose Escalation/Expansion, Phase 1/1b Study of IMU-201 (PD1-Vaxx), a B Cell Immunotherapy as Monotherapy or in Combination With Atezolizumab With or Without Chemotherapy, in Adults With Non-Small Cell Lung Cancer (NSCLC)

HER-Vaxx | HERIZON: A PHASE 2 STUDY OF HER-VAXX (IMU-131), A HER-2-TARGETING PEPTIDE VACCINE PLUS SOC CHEMOTHERAPY IN PATIENTS WITH HER-2+ ADVANCED STOMACH CANCER — CORRELATION OF THE ANTIBODY RESPONSES AND CLINICAL OUTCOME

onCARlytics: Effective combination immunotherapy using onCARlytics and ARTEMIS® CD19 T cells against hepatocellular carcinoma

CHECKvacc: hNIS imaging data from a first-in-human trial of the oncolytic virus CF33-hNIS-antiPD-L1 in patients with triple negative breast cancer

Presented by Dr Jamie Rand, Assistant Professor in the Division of Breast Surgery at the City of Hope’s Department of Surgery

HERIZON: A Phase 2 study of HER-Vaxx (IMU-131), a HER2 targeting peptide vaccine, plus standard of care chemotherapy in patients with HER2 overexpressing metastatic or advanced gastric/GEJ adenocarcinoma. Final Overall Survival Analysis

Presented by Dr Tanuj Chawla, MD

nextHERIZON: A PHASE 2 STUDY OF HER-VAXX, A HER-2 TARGETING PEPTIDE VACCINE, IN COMBINATION WITH CHEMOTHERAPY OR PEMBROLIZUMAB IN PATIENTS WITH HER-2 METASTATIC OR ADVANCED GASTRIC/GASTROESOPHAGEAL ADENOCARCINOMA WHO PROGRESSED ON OR AFTER TRASTUZUMAB TREATMENT

Presented by Dr Giovanni Selvaggi, Imugene CMO

Abstract 428: Development of a Novel Chimeric Oncolytic Viral Platform, CF33 and Its Derivatives, for Peritoneal-directed Treatment of Gastric Cancer Peritoneal Carcinomatosis

Presented by Dr Annie Yang, City of Hope

Abstract# 430: Ex vivo oncolytic and immune activity of CF33-hNIS-antiPDL1 against fresh peritoneal cells from gastric cancer patients with and without peritoneal metastases

Presented by Dr Yanghee Woo, City of Hope

Phase I study of intratumoral administration of CF33-hNIS-antiPD-L1 (CHECKvacc) in patients with metastatic triple negative breast cancer.

Presented by Dr Yuan Yuan M.D., PhD, Cedars Sinai Medicine, Los Angeles and Dr Jamie Rand M.D., City of Hope, Los Angeles. 

Developing Cancer Immunotherapies

HERIZON: A Phase 2 Study of HER-Vaxx (IMU-131),
a HER2-targeting Peptide Vaccine, Plus Standard
of Care Chemotherapy in Patients with HER2- Overexpressing Metastatic or Advanced Gastric/GEJ Adenocarcinoma— Overall Survival Analysis

Presented by Marina Maglakelidze, MD

Development of the B Cell Cancer Vaccine HER-Vaxx for the Treatment of Her-2 Expressing Cancers.

Presented by Imugene CTO, Dr Nick Ede

“CF33-CD19t oncolytic virus (onCARlytics) targets hepatocellular carcinoma (HCC) and in combination with CD19-Redirected ARTEMIS® T cells results in significant tumor killing.”

Presented by Dr Anthony Park from Dr Saul Priceman’s lab at City of Hope.

“CF33-CD19t oncolytic virus (onCARlytics) in combination with off-the-shelf allogeneic CYCART-19 T-cells targeting de novo CD19t expressing tumors.”

Presented by Dr Anthony Park from Dr Saul Priceman’s lab at City of Hope.

“Combination immunotherapy using a novel chimeric oncolytic virus to redirect CD19 bispecific T cell engagers to target solid tumors”.

Presented by Dr. Anthony Park, from Dr. Saul Priceman’s Lab at City of Hope.

Tobias etal. Outcome prediction of Her-2/neu targeting therapies in humans by pre-clinical evaluation in mice? Vaccination with a multi-peptide B cell vaccine targeting Trastzumab and Pertuzumab binding sites, suggests a combination with PD-L1-targeting therapy

Boyer etal. Phase 1: IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy as Monotherapy or in Combination with Atezolizumab, in Adults with Non-Small Cell Lung Cancer

Park etal, IMPRINTER: AN OPEN LABEL, MULTI-CENTER, DOSE ESCALATION/EXPANSION, PHASE I STUDY OF IMU-201 (PD1-VAXX), A B-CELL IMMUNOTHERAPY, IN ADULTS WITH NON-SMALL CELL LUNG CANCER

Marina Maglakelidze etal., HERIZON: A PHASE 1B/2 OPEN-LABEL STUDY OF IMU-131 HER2/NEU PEPTIDE VACCINE PLUS STANDARD OF CARE CHEMOTHERAPY WITH RANDOMIZATION IN PHASE 2 IN PATIENTS WITH HER2/NEU OVEREXPRESSING METASTATIC OR ADVANCED ADENOCARCINOMA OF THE STOMACH OR GASTROESOPHAGEAL JUNCTION’ Updated Interim Analysis Results

Laeufle etal. HERIZON: A phase 1B/2 open-label study of imu-131 HER2/neu peptide vaccine PLUS standard of care chemotherapy with randomization in phase 2 in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction.

Yanghee Woo etal., Subcutaneous Intratumoral Delivery of CF33-hNIS-antiPDL1 Eradicates Distant Peritoneal Tumors

Marina Maglakelidze etal., A PHASE 1B/2 OPEN-LABEL STUDY WITH RANDOMIZATION IN PHASE 2 OF IMU-131 HER2/NEU PEPTIDE IMMUNOTHERAPY PLUS STANDARD OF CARE CHEMOTHERAPY IN PATIENTS WITH HER2/NEU OVEREXPRESSING METASTATIC OR ADVANCED ADENOCARCINOMA OF THE STOMACH OR GASTROESOPHAGEAL JUNCTION

Dr Pravin Kaumaya, Ohio State University. A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types.

Yee Chao, Thomas Cheung Yau and Marina Maglakelidze etal.: A phase 1b study of imu-131 her2/neu peptide vaccine plus chemotherapy in patients with her2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction

Joshua Tobias etal.: Active immunization with immune checkpoint inhibitors-mimotope elicits strong in vivo anti-tumor effect against Her-2/neu-expressing tumors

Pravin T.P Kaumaya etal.: Abstract 1218P: Antitumor activity and safety of a novel PD-1 vaccine (PD1-Vaxx) alone and in combination with two chimeric HER-2 peptide vaccine (B-Vaxx) in syngeneic Balb/c mice and canines

Ursula Wiedermann etal.: Comprehensive results of a Phase Ib study with a HER2/neu B-cell peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy show safety, immunogenicity and clinical response in patients with HER2/neu overexpressing advanced gastric cancer

Dr Marina Maglakelidze etal.: ‘A Phase 1B study of IMU-131 HER2/NEU peptide vaccine plus chemotherapy in patients with HER2/NEU overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction.’

Dr Marina Maglakelidze etal.: ‘A Phase 1B study of IMU-131 HER2/NEU peptide vaccine plus chemotherapy in patients with HER2/NEU overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction.’

Dr Yee Chao etal.: ‘A Phase 1B study of IMU-131 HER2/NEU peptide vaccine plus chemotherapy in patients with HER2/NEU overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction.’

Tanios Bekaii-Saab etal.: Abstract 1453: Development of a novel PD-1 vaccine and in combination with two Chimeric HER-2 peptide vaccine provides synergistic inhibition of tumor growth in a syngeneic Balb/c model challenged with CT26/HER-2 carcinoma cell line

Tanios Bekaii-Saab etal.: Abstract CT 017: Phase Ib Immunotherapy Trial with a Combination of Two Chimeric (Trastuzumab-like and Pertuzumab-like) HER-2 B Cell Peptide Vaccine emulsified in ISA 720 and nor-MDP Adjuvant in Patients with Advanced Solid Tumors, Immunological Response and Clinical Outcome

Ursula Wiedermann etal.: A Phase Ib open label multicenter study with a HER2/neu peptide vaccine administered with cisplatin and 5-fluoroouracil or capecitabine chemotherapy shows safety, immunogenicity and clinical response in patients with HER2/neu overexpressing advanced cancer of the stomach

Joshua Tobias etal.: PD1 B cell mimotopes with functional PD1-PDL1 blocking capacity and anti-tumor activity: New strategy for a multi-level cancer immunotherapy

Ursula Wiedermann etal.: ‘A Phase Ib open label multicenter study with a HER2/neu peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy shows safety, immunogenicity and clinical response in patients with HER2/Neu overexpressing advanced cancer of the stomach.’